- $3.36bn
- $3.36bn
- $12.80m
Ekso Bionics Holdings Inc reports results for the quarter ended in June - Earnings Summary
Ekso Bionics Holdings Inc expected to post a loss of 24 cents a share - Earnings Preview
Ekso Bionics climbs on FDA nod for use of robotic exoskeleton on MS patients
Brief: Ekso Bionics Receives FDA Clearance To Market Its Eksonr Robotic Exoskeleton For Use With Multiple Sclerosis Patients
Brief: Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer
Germany's Ottobock delays IPO due to market turmoil
Ekso Bionics Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ekso Bionics Reports First Quarter 2022 Results
Ekso Bionics Holdings Inc expected to post a loss of 41 cents a share - Earnings Preview
Ekso Bionics Holdings Inc reports results for the quarter ended in December - Earnings Summary
Ekso Bionics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview
Germany's Ottobock to wait until September to list amid choppy markets - sources
Brief: Ekso Bionics Holdings Inc Says Steven Sherman To Be Appointed CEO
Brief: Ekso Bionics Reports Preliminary Q4 And Full Year 2021 Financial Results
Brief: Ekso Bionics Appoints Corinna Lathan To Board Of Directors
Brief: Ekso Bionics Announces Eksonr Multi-Unit Order By Nebraska Fraternal Order Of Eagles
Brief: Ekso Bionics Posts Q3 Loss Per Share Of $0.17
Ekso Bionics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview
Ekso Bionics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview